Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

USAMRIID Seeks Animal Vaccination Services for Immunogenicity Studies

by Global Biodefense Staff
March 31, 2014

The Virology Division at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Md. has a requirement to evaluate the immunogenicity of a novel vaccine platform administered in multiple formulations (28 or 56 days apart) by intramuscular injection to Cynomolgus macaques.

The vendor must be capable of pre-screening all animals and confirm they are negative for the following pathogens: Filoviruses, Alphaviruses, tuberculosis, HMV phenotype of Klebsiella pneumoniae, shigella, salmonella, and Yersinia. The vendor must be able to collect whole blood in serum separator (SST), EDTA K2, Na citrate, and CPT Heparin collection tubes at various time points both pre- and post-vaccination of the animals.

After blood collection, the vendor must be able to process each sample and aliquot accordingly for serum (SST), whole blood (EDTA K2), plasma (Na Citrate), and PBMCs (CPT Heparin) and ship the samples to USAMRIID for additional analysis. If during USAMRIID analysis, it is determined that the animals produced an adequate immune response to the vaccine, the vendor will ship the animals to USAMRIID for additional evaluation; if the animals do not produce an adequate response to the vaccine, then the vendor will dispose of the animals according to their own institute policies and procedures.

Further details are available under Solicitation Number: Solicitation Number: W81XWH-14-T-0112. The response deadline is April 14, 2014.

Tags: ShigellaUSAMRIIDVaccinesY. pestis

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy